Mutations in the SBDS gene in acquired aplastic anemia

Blood

Volumn 110, Issue 4, 2007, Pages 1141-1146

  Calado, Rodrigo T ^a   Graf, Solomon A ^a,b   Wilkerson, Keisha L ^a   Kajigaya, Sachiko ^a   Ancliff, Philip J ^c   Dror, Yigal ^d   Chanock, Stephen J ^e   Lansdorp, Peter M ^f   Young, Neal S ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^d HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^e NATIONAL CANCER INSTITUTE   (United States)

^f UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; APLASTIC ANEMIA; ARTICLE; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DNA POLYMORPHISM; ETHNIC GROUP; FEMALE; GENE; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENETIC SCREENING; HETEROZYGOSITY; HUMAN; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; RISK FACTOR; SBDS GENE; SHWACHMAN SYNDROME; TELOMERE;

EID: 34548039210     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-03-080044     Document Type: Article

References (29)

1. Dror Y. Shwachman-Diamond syndrome. Pediatr Blood Cancer. 2005;45:892-901.
2. Thornley I, Dror Y, Sung L, Wynn RF, Freedman MH. Abnormal telomere shortening in leucocytes of children with Shwachman-Diamond syndrome. Br J Haematol. 2002;117:189-192.
3. Savchenko A, Krogan N, Cort JR, et al. The Shwachman-Bodian-Diamond syndrome protein family is involved in RNA metabolism. J.Biol Chem. 2005;280:19213-19220.
4. Austin KM, Leary RJ, Shimamura A. The Shwachman-Diamond SBDS protein localizes to the nucleolus. Blood. 2005;106:1253-1258.
5. Boocock GR, Morrison JA, Popovic M, et al. Mutations in SBDS are associated with Shwachman-Diamond syndrome. Nat Genet. 2003;33:97-101.
6. Vulliamy T, Dokal I. Dyskeratosis congenita. Semin Hematol. 2006;43:157-166.
7. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108:2511-2521.
8. Blackburn EH. Switching and signaling at the telomere. Cell. 2001;106:661-673.
9. Muntoni A, Reddel RR. The first molecular details of ALT in human tumor cells. Hum Mol Genet. 2005;14:R191-R196.
10. Brummendorf TH, Maciejewski JP, Young NS, Lansdorp PL. Telomere length in leukocyte subpopulations of patients with aplastic anemia. Blood. 2001;97:895-900.
11. Vulliamy TJ, Knight SW, Mason PJ, Dokal I. Very short telomeres in the peripheral blood of patients with x-linked and autosomal dyskeratosis congenita. Blood Cells Mol Dis. 2001;27:353-357.
12. Yamaguchi H, Calado RT, Ly H, et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Eng J Med. 2005;352:1413-1424.
13. Xin ZT, Beauchamp AD, Calado RT, et al. Functional characterization of natural telomerase mutations found in patients with hematological disorders. Blood. 2007;109:524-532.
14. Fogarty PF, Yamaguchi H, Wiestner A, et al. Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA. Lancet. 2003;362:1628-1630.
15. Heiss NS, Knight SW, Vulliamy TJ, et al. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat Genet. 1998;19:32-38.
16. Vulliamy T, Marrone A, Goldman F, et al. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature. 2001;413:432-435.
17. Kaufman DW, Kelly JP, Levy M, Shapiro S. The Drug Etiology of Agranulocytosis and Aplastic Anemia. New York, NY: Oxford; 1991.
18. Packer BR, Yeager M, Staats B, et al. SNP500-Cancer: a public resource for sequence validation and assay development for genetic variation in candidate genes. Nucleic Acids Res. 2004;32:D528-D532.
19. Ginzberg H, Shin J, Ellis L, et al. Shwachman syndrome: phenotypic manifestations of sibling sets and isolated cases in a large patient cohort are similar. J Pediatr. 1999;135:81-88.
20. Woloszynek JR, Rothbaum RJ, Rawls AS, et al. Mutations of the SBDS gene are present in most patients with Shwachman-Diamond syndrome. Blood. 2004;104:3588-3590.
21. Baerlocher GM, Lansdorp PL. Telomere length measurements in leukocyte subsets by automated multicolor flow-FISH. Cytometry. 2003;55A:1-6.
22. Zhang S, Shi M, Hui CC, Rommens JM. Loss of the mouse ortholog of the shwachman-diamond syndrome gene (Sbds) results in early embryonic lethality. Mol Cell Biol. 2006;26:6656-6663.
23. Maciejewski JP, Risitano AM, Sloand EM, Nunez O, Young NS. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. Blood. 2002;99:3129-3135.
24. Yamaguchi M, Fujimura K, Toga H, et al. The SBDS gene regulates viability of myeloid precursor cells and is associated with high ROS production and telomere shortening in the SBDS down-regulated cells [abstract]. Blood. 2006;108:1639.
25. Wessels D, Srikantha T, Yi S, et al. The Shwachman-Bodian-Diamond syndrome gene encodes an RNA-binding protein that localizes to the pseudopod of Dictyostelium amoebae during chemotaxis. J Cell Sci. 2006;119:370-379.
26. Herrera E, Martinez AC, Blasco MA. Impaired germinal center reaction in mice with short telomeres. EMBO J. 2000;19:472-481.
27. Strahl C, Blackburn EH. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol Cell Biol. 1996;16:53-65.
28. Yeager TR, Neumann AA, Englezou A, et al. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res. 1999;59:4175-4179.
29. Fasching CL, Bower K, Reddel RR. Telomerase-independent telomere length maintenance in the absence of alternative lengthening of telomeres-associated promyelocytic leukemia bodies. Cancer Res. 2005;65:2722-2729.